Altana Inc. BY217/M2-111 (Murray) 03/15/04 - 04/12/06
Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease. A 52 Week Double-Blind multicenter study with 500 mcg roflumilast once daily versus placebo
AstraZeneca SD-039-0725 (Murray) 03/01/03 - 03/17/05
A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 Years of Age with Asthma-SPROUT
AstraZeneca SD-004-0620 (Murray) 10/07/02 - 07/12/05
A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turuhaler® in Asthmatic Adults and Adolescents Currently Treated with Inhaled Steroids
AstraZeneca SD-004-0726 (Murray) 1/20/02 - 09/30/04
A Comparison of he Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort Turbuhaler® and the New Version of Pulmicort Turbuhaler® in asthmatic children
Genentech Q2948g (Murray) 10/21/04 - 12/01/11
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long Term Safety in Patients with Moderate to Severe Asthma
GlaxoSmithKline FFR100010 (Murray) 02/25/05 - 04/14/06
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 1 to <12 Years with Seasonal Allergic Rhinitis
GlaxoSmithKline FFR30002 (Murray) 02/15/05 - 03/14/06
"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg for 4 weeks in Adult and Adolescent Subject (≥12 years of age) with Perennial Allergic Rhinitis (PAR)
Murray, John J., M.D., Ph.D. (Continued)
GlaxoSmithKline MHE 100185 (Murray) 07/22/04 - 05/11/06
A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-Reduction and Sparing Effects of Mepolizumab 750 mg Intravenous in Subjects with Hypereosinophilic Syndromes (HES), and to Evaluate the Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of HES over Nine Months
GlaxoSmithKline MHE100901 (Murray) 03/07/05 - 11/28/07
An Open Label Extension Study to Study 100185, to Evaluate Long-Term Safety, Efficacy and Optimal Dosing Frequency of 750mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndrome
Merck: (Murray) 01/08/04 – 10/30/04
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to E valuate the Clinical Effect of Oral Montelukast Versus Placebo During the Allergy Season in Patients with Seasonal Aeroallergen Sensitivity and Chronic Asthma which is also Active During Allergy Season. Protocol No. 289/SNG554. Principal Investigator. 2004.
GlaxoSmithKline SFA100062 (Murray) 01/15/05 - 01/14/06
A Randomized-Parllel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated with Fluticasone Propionate/Salmeterold DISKUS® Combination Product 100/50mct of Salmeterol DISKUS® 50mcg BID
GlaxoSmithKline SFA100316 (Murray) 12/17/03 - 01/01/06
A Stratified, Multicenter, Randomized, Double-Blind paralled B Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm
King Pharmaceuticals MRE0470-203 (Murray) 11/01/03 - 10/26/05
Two-Part Study to Evaluate the Safety of Binodenoson (MRE0470) in Adult Subjects with Mild, Intermittent Asthma
Novartis IGE025AIA05 (Murray) 02/14/05 - 12/14/06
A 1 Year, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of omalizumab in children (6-<12years) with moderate-severe, persistent, inadequately controlled allergic asthma
GSK SFA103153 (Murray) 03/01/05 - 02/28/06
A Multicenter, Randomized, Double-Blind, Parallel Group, 52 Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS BID or Fluticasone Propionate 100mcg DISKUS BID alone
Pfizer/ Quintiles WA18063RG; WA18063B (Tanner) 08/10/05 - 04/10/07
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy
Pfizer (Murray) 04/30/05 – 05/01/06
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study of the Efficacy and Safety of Tofimilast Dry Powder for Inhalation in Adults with Persistent Asthma.
Pfizer/Aventis (Murray) 06/01/03 – 9/30/06
Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial. |
Murray JJ, J Nowak, JA Oates and GA FitzGerald. Platelet-vascular interaction during chronic smoking in man. Advances Exper Med Biol 273: 189-198, 1990.
Sasaki K, Y Yamano, S Bardhan, N Iwai, JJ Murray, M Hasegawa and T Inagami. Cloning and expression of a cDNA encoding a bovine adrenal angiotensin II type-1 receptor.Nature 351: 230-233, 1991.
Kane G, Pollice M, Cohn J, Murray JJ, Fish J, Peters S. Controlled trial of the effect of a 5-LO inhibitor on lung inflammation produced by segmental antigen challenge. J Aller Clin Immunol. 93:184, 1994.
Mullins MD, Serafin WE, Murray JJ. Immunomodulatory effects of the stable prostaglandin E analog misoprostol in vivo. J Aller Clin Immunol. 93:203, 1994.
Velasco CE, Turner M, Kondo T, Inagami T, Atkinson JB, Virmani R, Jackson EK, Murray JJ, Forman MB. Enhanced local endothelin release following myocardial ischemia and reperfusion contributes to "no-reflow" phenomenon. Am Heart J. 128:441-51, 1994.
Murray JJ, Mullins MD, Knapp H, Keeler SL, Serafin WE, Keane B, Roberts LJ II, Struthers BJ, Oates JA. Regulation of the immune response by eicosanoids: Pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. Am J Therapeut. 2:739-748, 1995.
Kane G, Pollice M, Cohn J, Dworski R, Murray J, Sheller J, Kim C-J, Fish J, Peters S. Insights into mechanisms of IGE mediated human lung inflammation derived from segmental antigen challenge studies employing a 5-lipoxygenase inhibitor. J Aller Clin Immunol. 97:646-654, 1996.
Israel E, Cohn J, Dube L, Drazen JM and the Zileuton Clinical Trial Group. Effect of treatment with Zileuton, a 5-lipoxygeanse inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 275:931-936, 1996.
Vitola JV,Holsinger JP,Atkinson JB,Forman MB,Murray JJ.Inhibition of neutrophil activation as a mechanism for the reduction of myocardial reperfusion injury by lidocaine in the rabbit model. Am Heart J.133:315-322, 1997.
In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, DeSanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ,Segal A,Tinkelman D,Drazen JM. Naturally occurring mutations in the 5-lipoxygenase gene promoter that modify transcroption factor binding and reporter gene transcription. J Clin Invest. 99:1130-1137, 1997.
Busse WW, Casale TB, Murray JJ, Petrocella V, Cox F and K Rickard. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. Am J Managed Care. 4:1579-87, 1998.
Murray JJ, NL Church, WA Anderson, DI Bernstein, SE Wenzel, A Emmett and KA Rickard. Concurrent use of salmeterol with inhaled steroids is more effective than steroid-dose increases. Allergy Asthma Proc. 20:173-180, 1999.
Stein CM, JJ Murray and AJJ Wood. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporin effect. Clin Chem. 45:1477-84, 1999.
Dworski R, Murray JJ, Roberts LJ 2nd, Oates JA, Morrow JD, Fisher L, Sheller JR. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med. 160(6):1947-1951, 1999.
Hartert TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR. Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma.rostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma. Am J Respir Crit Care Med. 162(2 Pt 1):637-640, 2000.
Murray JJ, Solomon E, McCluskey D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther. 2000 Dec;22(12):1421-32.
Raddassi K, Murray JJ. Ethanol increases superoxide anion production stimulated with 4beta-phorbol 12-myristate13-acetate in human polymorphonuclear leukocytes. Involvement of protein kinase C. Eur J Biochem. 267(3):720-727, 2000.
Dahlen B, Szczeklik A, Murray JJ; Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group.
N Engl J Med. 2001 Jan 11;344(2):142.
Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002 Nov-Dec;23(6):391-8.
Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 120(2):423-430, 2001.
Sheller JR, Dworski R, Hagaman D, Oates J, Murray J. The prostaglandin E agonist, misoprostol, inhibits airway IL-5 production in atopic asthmatics. Prostaglandins & Other Mediators. 70:185-193, 2002.
Sheller JR, Dworski R, Hagaman D, Oates J, Murray J. The E prostaglandin agonist, misoprostol, inhibits airway IL-5 production in atopic asthmatics. Intl Arch Aller Immunol. 70(1-2):185-193, 2002.
Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 115(7):587-589, 2003.
Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 115(7):587-589, 2003.
Lumry W, Hampel F, LaForce C, Kiechel F, el-Akkad T, Murray JJ. A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc.24(3):203-210, 2003.
Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 113(1):59-65, 2004.
Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 2004 Oct;93(4):351-9.
Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg. 2005 Aug;133(2):194-200.
Murray JJ. Cardiovascular risks associated with beta-agonist therapy. Chest. 2005 Jun;127(6):2283-5.
Amrol DJ, Hagaman DD, Sheller JR, Murray JJ. Soluble CD23 and interleukin-1 receptor antagonist in human asthmatics following antigen challenge. J Asthma. 42(1):73-76, 2005. |
Education 
Research
Patient Care
Links
